Aurinia Pharmaceuticals Inc. (AUPH)

$9.29

+0.55 (+6.29%)
Rating:
Recommendation:
Neutral
Symbol AUPH
Price $9.29
Beta 1.160
Volume Avg. 3.26M
Market Cap 1.325B
Shares () -
52 Week Range 4.07-13.415
1y Target Est -
DCF Unlevered AUPH DCF ->
DCF Levered AUPH LDCF ->
ROE -25.44% Sell
ROA -22.97% Sell
Operating Margin -
Debt / Equity 16.14% Neutral
P/E -12.73 Strong Sell
P/B 3.25 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest AUPH news


Mr. Peter S. Greenleaf M.B.A.
Healthcare
Biotechnology
NASDAQ Global Market

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.